Iwatsuki, Y.; Sato, T.; Moritani, Y.; Shigenaga, T.; Suzuki, M.; Kawasaki, T.; Funatsu, T.; Kaku, S. (2011). "Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor". European Journal of Pharmacology. 673 (1–3): 49–55. doi:10.1016/j.ejphar.2011.10.009. PMID22040919.
Shiraga, T.; Yajima, K.; Suzuki, K.; Suzuki, K.; Hashimoto, T.; Iwatsubo, T.; Miyashita, A.; Usui, T. (2012). "Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 40 (2): 276–82. doi:10.1124/dmd.111.042614. PMID22031623. S2CID1643706.
Hylek, E. M.; Go, A. S.; Chang, Y.; Jensvold, N. G.; Henault, L. E.; Selby, J. V.; Singer, D. E. (2003). "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation". The New England Journal of Medicine. 349 (11): 1019–26. doi:10.1056/NEJMoa022913. PMID12968085.
Hirayama, F.; Koshio, H.; Ishihara, T.; Hachiya, S.; Sugasawa, K.; Koga, Y.; Seki, N.; Shiraki, R.; Shigenaga, T.; Iwatsuki, Y.; Moritani, Y.; Mori, K.; Kadokura, T.; Kawasaki, T.; Matsumoto, Y.; Sakamoto, S.; Tsukamoto, S. (2011). "Discovery of N-2-hydroxy-6-(4-methoxybenzamido)phenyl-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a potent and orally available factor Xa inhibitor". Journal of Medicinal Chemistry. 54 (23): 8051–65. doi:10.1021/jm200868m. PMID21995444.
Iwatsuki, Y.; Sato, T.; Moritani, Y.; Shigenaga, T.; Suzuki, M.; Kawasaki, T.; Funatsu, T.; Kaku, S. (2011). "Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor". European Journal of Pharmacology. 673 (1–3): 49–55. doi:10.1016/j.ejphar.2011.10.009. PMID22040919.
Shiraga, T.; Yajima, K.; Suzuki, K.; Suzuki, K.; Hashimoto, T.; Iwatsubo, T.; Miyashita, A.; Usui, T. (2012). "Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 40 (2): 276–82. doi:10.1124/dmd.111.042614. PMID22031623. S2CID1643706.
Hylek, E. M.; Go, A. S.; Chang, Y.; Jensvold, N. G.; Henault, L. E.; Selby, J. V.; Singer, D. E. (2003). "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation". The New England Journal of Medicine. 349 (11): 1019–26. doi:10.1056/NEJMoa022913. PMID12968085.
Hirayama, F.; Koshio, H.; Ishihara, T.; Hachiya, S.; Sugasawa, K.; Koga, Y.; Seki, N.; Shiraki, R.; Shigenaga, T.; Iwatsuki, Y.; Moritani, Y.; Mori, K.; Kadokura, T.; Kawasaki, T.; Matsumoto, Y.; Sakamoto, S.; Tsukamoto, S. (2011). "Discovery of N-2-hydroxy-6-(4-methoxybenzamido)phenyl-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a potent and orally available factor Xa inhibitor". Journal of Medicinal Chemistry. 54 (23): 8051–65. doi:10.1021/jm200868m. PMID21995444.
Shiraga, T.; Yajima, K.; Suzuki, K.; Suzuki, K.; Hashimoto, T.; Iwatsubo, T.; Miyashita, A.; Usui, T. (2012). "Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 40 (2): 276–82. doi:10.1124/dmd.111.042614. PMID22031623. S2CID1643706.